دورية أكاديمية
Molecular profiling refines minimal residual disease-based prognostic assessment in adults with Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia
| العنوان: | Molecular profiling refines minimal residual disease-based prognostic assessment in adults with Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia |
|---|---|
| المؤلفون: | Ribera, Jordi, Zamora, Lurdes, Morgades, Mireia, Vives, Susana, Granada, Isabel, Montesinos, Pau, Gómez‐Seguí, Inés, Mercadal, Santiago, Guàrdia, Ramón, Nomdedéu, Josep F., Pratcorona, Marta, Tormo, Mar, Martínez‐Lopez, Joaquín, Hernández, Jesús M., Ciudad, Juana, Orfao, Alberto, González‐Campos, José, Barba, Pere, Escoda, Lourdes, Esteve, Jordi, Genescà, Eulàlia, Solé, Francesc, Feliu, Evarist, Ribera, Josep-Maria |
| المساهمون: | Josep Carreras Leukemia Foundation, Generalitat de Catalunya, Instituto de Salud Carlos III, European Commission, Fundación "la Caixa", Sociedad Española de Hematología y Hemoterapia |
| بيانات النشر: | Wiley-Liss |
| سنة النشر: | 2019 |
| المجموعة: | Digital.CSIC (Consejo Superior de Investigaciones Científicas / Spanish National Research Council) |
| الوصف: | Minimal residual disease (MRD) assessment is an essential tool in contemporary acute lymphoblastic leukemia (ALL) protocols, being used for therapeutic decisions such as hematopoietic stem cell transplantation in high‐risk patients. However, a significant proportion of adult ALL patients with negative MRD still relapse suggesting that other factors (ie, molecular alterations) must be considered in order to identify those patients with high risk of disease progression. We have identified partial IKZF1 gene deletions and CDKN2A/B deletions as markers of disease recurrence and poor survival in a series of uniformly treated adolescent and adult Philadelphia chromosome‐negative B‐cell progenitor ALL patients treated according to the Programa Español de Tratamientos en Hematología protocols. Importantly, CDKN2A/B deletions showed independent significance of MRD at the end of induction, which points out the need for treatment intensification in these patients despite being MRD‐negative after induction therapy. ; Fundació Internacional Josep Carreras; Generalitat de Catalunya, Grant/Award Number: 2017 SGR 288 GRC; Instituto de Salud Carlos III; Ministerio de Salud Carlos III RTICC‐FEDER, Grant/Award Numbers: RD12/0036/0029, RD/0036/044; Obra Social “La Caixa”; Sociedad Española de Hematología y Hemoterapia; Fondo de Investigaciones Sanitarias, Grant/Award Numbers: PI14/01971, PI10/01417 |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | unknown |
| تدمد: | 1045-2257 1098-2264 |
| العلاقة: | http://dx.doi.org/10.1002/gcc.22788Test; Sí; Genes Chromosomes and Cancer 58(11): 815-819 (2019); http://hdl.handle.net/10261/203599Test; http://dx.doi.org/10.13039/501100002809Test; http://dx.doi.org/10.13039/501100000780Test; http://dx.doi.org/10.13039/501100008782Test; http://dx.doi.org/10.13039/501100004587Test; http://dx.doi.org/10.13039/501100005677Test |
| DOI: | 10.1002/gcc.22788 |
| DOI: | 10.13039/501100002809 |
| DOI: | 10.13039/501100000780 |
| DOI: | 10.13039/501100008782 |
| DOI: | 10.13039/501100004587 |
| DOI: | 10.13039/501100005677 |
| الإتاحة: | https://doi.org/10.1002/gcc.22788Test https://doi.org/10.13039/501100002809Test https://doi.org/10.13039/501100000780Test https://doi.org/10.13039/501100008782Test https://doi.org/10.13039/501100004587Test https://doi.org/10.13039/501100005677Test http://hdl.handle.net/10261/203599Test |
| حقوق: | none |
| رقم الانضمام: | edsbas.22D0733D |
| قاعدة البيانات: | BASE |
| تدمد: | 10452257 10982264 |
|---|---|
| DOI: | 10.1002/gcc.22788 |